180 Life Sciences Corp. (NASDAQ:ATNF) has identified a new synthetic CBD analog that is non-psychoactive and could have benefits in the reduction of inflammation and pain, the company announced on Wednesday. The clinical-stage biotechnology company is focused on the development of novel drugs to treat inflammatory diseases, fibrosis and pain.

Arena Pharmaceuticals is ponying up $60 million upfront and investing $10 million in Aristea Therapeutics to collaborate on the latter’s inflammatory disease program and snag the option to acquire its partner. Arena also chipped into Aristea’s $63 million series B round, led by Fidelity Management & Research Company. Aristea, an AstraZeneca spinout, is developing the […]

As a biotech company on the forefront of nerve repair treatment, Axogen has always been near the front of the scientific curve. But they’ve also done okay on the real estate front. Three years ago, the company, founded in Gainesville, signed a 75,000-square-foot lease for a second headquarters at Tampa’s Heights Union, which was at […]